IN8bio Announces 1-for-30 Reverse Stock Split

IN8bio ( (INAB) ) has provided an update.

On June 3, 2025, IN8bio, Inc. announced a reverse stock split at a ratio of 1-for-30, which was authorized by its stockholders on May 8, 2025. Effective June 5, 2025, this move will proportionately adjust stock options, warrants, and shares reserved under the company’s equity plans, with no fractional shares issued. The company’s common stock will trade on a split-adjusted basis on Nasdaq starting June 6, 2025, reducing outstanding shares from 103,327,028 to approximately 3,444,234.

The most recent analyst rating on (INAB) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.

Spark’s Take on INAB Stock

According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.

IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.

To see Spark’s full report on INAB stock, click here.

More about IN8bio

Average Trading Volume: 2,928,632

Technical Sentiment Signal: Sell

Current Market Cap: $12.14M

Find detailed analytics on INAB stock on TipRanks’ Stock Analysis page.